ESMO 2026: Highlights and analysis

Lifileucel plus pembrolizumab shows durable responses in first-line advanced melanoma

T-cell engagers in mAPMR/mCRPC

Intismeran plus pembrolizumab improves recurrence free survival in resected high risk melanoma

HBI-8000 plus nivolumab significantly improves progression-free survival in advanced melanoma

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

WCLC 2026: Lung cancer research highlights

Isa-VRd shows sustained benefit in transplant-ineligible newly diagnosed multiple myeloma

Subcutaneous tarlatamab shows promising safety and activity in previously treated extensive-stage SCLC

Adagrasib plus cetuximab shows activity but does not improve survival in KRAS G12C-mutated metastatic colorectal cancer

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS